SG11201503245PA - Platelet-derived growth factor b specific antibodies and compositions and uses thereof - Google Patents

Platelet-derived growth factor b specific antibodies and compositions and uses thereof

Info

Publication number
SG11201503245PA
SG11201503245PA SG11201503245PA SG11201503245PA SG11201503245PA SG 11201503245P A SG11201503245P A SG 11201503245PA SG 11201503245P A SG11201503245P A SG 11201503245PA SG 11201503245P A SG11201503245P A SG 11201503245PA SG 11201503245P A SG11201503245P A SG 11201503245PA
Authority
SG
Singapore
Prior art keywords
platelet
compositions
uses
growth factor
specific antibodies
Prior art date
Application number
SG11201503245PA
Inventor
Robert Arch
Gregory Carven
Jun Kuai
Lydia Mosyak
Shinji Ogawa
Dirk Ponsel
Robert Rauchenberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261724888P priority Critical
Application filed by Pfizer filed Critical Pfizer
Priority to PCT/IB2013/059718 priority patent/WO2014072876A1/en
Publication of SG11201503245PA publication Critical patent/SG11201503245PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201503245PA 2012-11-09 2013-10-28 Platelet-derived growth factor b specific antibodies and compositions and uses thereof SG11201503245PA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201261724888P true 2012-11-09 2012-11-09
PCT/IB2013/059718 WO2014072876A1 (en) 2012-11-09 2013-10-28 Platelet-derived growth factor b specific antibodies and compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11201503245PA true SG11201503245PA (en) 2015-05-28

Family

ID=49955419

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503245PA SG11201503245PA (en) 2012-11-09 2013-10-28 Platelet-derived growth factor b specific antibodies and compositions and uses thereof

Country Status (14)

Country Link
EP (1) EP2917237A1 (en)
JP (1) JP2015536339A (en)
KR (1) KR20150082503A (en)
CN (1) CN105026426A (en)
AR (1) AR093394A1 (en)
AU (1) AU2013343099A1 (en)
CA (1) CA2890483A1 (en)
HK (1) HK1216428A1 (en)
IL (1) IL238568D0 (en)
MX (1) MX2015005874A (en)
RU (1) RU2015115956A (en)
SG (1) SG11201503245PA (en)
TW (1) TWI522364B (en)
WO (1) WO2014072876A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CN105085652A (en) * 2014-05-16 2015-11-25 中国人民解放军军事医学科学院生物工程研究所 Platelet-derived growth factor-B mutant and preparation method and application thereof
PE01922017A1 (en) 2014-07-17 2017-03-16 Novo Nordisk As Site directed mutagenesis trigger receptor antibodies expressed in type 1 (trem-1) to reduce the viscosity meloid
EP2975056A1 (en) * 2014-07-17 2016-01-20 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
CN107148429A (en) * 2014-11-10 2017-09-08 豪夫迈·罗氏有限公司 Anti-pdgf-b antibodies and methods of use
JP2017534646A (en) 2014-11-10 2017-11-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Anti-IL-1 Beta Antibody and Method of Use
BR112017009764A2 (en) * 2014-11-10 2018-02-20 Hoffmann La Roche bispecific antibodies and methods of use in ophthalmology
EP3026061A1 (en) * 2014-11-26 2016-06-01 Novo Nordisk A/S Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
CN105732809B (en) * 2014-12-31 2019-08-06 广东众生药业股份有限公司 The antibody of antiplatelet derivative factor
CN107849126A (en) 2015-07-29 2018-03-27 阿勒根公司 Heavy chain only antibodies to ang-2
CA2992788A1 (en) * 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974B1 (en) 1978-01-06 1982-12-03 David Bernard
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc Method for coupling liposomes.
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Denaturation antibody, or improvements relating modified antibody
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biolog Expression of retrovirus gag protein eukaryotic cells
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AT165516T (en) 1989-03-21 1998-05-15 Vical Inc Expression of exogenous polynucleotide sequences in vertebrate animals
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0605522B1 (en) 1991-09-23 1999-06-23 Cambridge Antibody Technology Limited Methods for the production of humanized antibodies
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
JPH06507404A (en) 1991-05-01 1994-08-25
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ES2197145T3 (en) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Gene transfer mediated gastrointestinal adenovirus.
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
FR2688514B1 (en) 1992-03-16 1994-12-30 Centre Nat Rech Scient
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California Methods and compositions for targeting specific tissue.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
DE69308573D1 (en) 1992-08-17 1997-04-10 Genentech Inc bispecific immunoadhesine
JPH08503855A (en) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション Gene therapy for cystic fibrosis
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ES2249761T3 (en) 1993-06-24 2006-04-01 Advec Inc. Adenovirus vectors for gene therapy.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2523216C (en) 1993-09-15 2010-11-16 Chiron Corporation Recombinant alphavirus vectors
NZ275956A (en) 1993-10-25 1997-09-22 Canji Inc A recombinant adenovirus expression vector useful against tumours
BR9408072A (en) 1993-11-16 1997-08-12 Depotech Corp Vesicles with controlled release of active
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
ES2395214T3 (en) 1996-03-04 2013-02-11 The Penn State Research Foundation Materials and methods to increase cellular internalization
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306D1 (en) 1997-01-16 2005-02-24 Massachusetts Inst Technology Preparation of particle-containing medicinal products for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab The encapsulation method for active substance in a biodegradable polymer
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1144607B1 (en) 1999-07-20 2008-12-17 MorphoSys AG Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc Fc varieties with optimized fc receptor binding properties
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2562177T3 (en) 2002-09-27 2016-03-02 Xencor Inc. Optimized Fc variants and methods for their generation
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
ES2382918T3 (en) 2002-12-24 2012-06-14 Rinat Neuroscience Corp. Anti-NGF antibodies and procedures using them
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
KR20080077347A (en) * 2005-07-28 2008-08-22 아르만도 가브리엘리 Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target
AU2006283725B2 (en) 2005-08-19 2012-02-16 The Trustees Of The University Of Pennsylvania Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
CL2007002225A1 (en) * 2006-08-03 2008-04-18 Astrazeneca Ab Specific binding agent for a receptor of platelet-derived growth factor (PDGFR-alpha); nucleic acid molecule encoding it; vector and host cell comprising it; conjugate comprising the agent; and use of an agent
ME01786B (en) 2006-08-14 2014-09-20 Xencor Inc Optimized antibodies that target cd19
LT2176298T (en) 2007-05-30 2018-04-10 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
LT3190128T (en) 2008-09-17 2019-01-10 Xencor, Inc. Compositions and methods for treating ige-mediated disorders

Also Published As

Publication number Publication date
CN105026426A (en) 2015-11-04
CA2890483A1 (en) 2014-05-15
TWI522364B (en) 2016-02-21
HK1216428A1 (en) 2016-11-11
JP2015536339A (en) 2015-12-21
AU2013343099A1 (en) 2015-05-14
WO2014072876A1 (en) 2014-05-15
AR093394A1 (en) 2015-06-03
RU2015115956A (en) 2017-01-10
IL238568D0 (en) 2015-06-30
TW201431878A (en) 2014-08-16
EP2917237A1 (en) 2015-09-16
MX2015005874A (en) 2015-09-10
KR20150082503A (en) 2015-07-15

Similar Documents

Publication Publication Date Title
IL230596D0 (en) N-thio-anthranilamide compounds and their use as pesticides
HK1213016A1 (en) Cell modifying compounds and uses thereof
HUE041987T2 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
IL237156A (en) Microcapsule compositions and methods
EP2879708A4 (en) Anti-etbr antibodies and immunoconjugates
IL233934D0 (en) Cd47 antibodies, compositions comprising the same and uses thereof
EP2756094A4 (en) Anti-b7-h4 antibodies and their uses
IL234719D0 (en) Anti-pmel17 antibodies and immunoconjugates
SG11201405881TA (en) Anti-lgr5 antibodies and immunoconjugates
IL238958D0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
IL236348D0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
HK1205751A1 (en) Conjugates, particles, compositions, and related methods
EP2836212A4 (en) Novel compositions and methods
EP2888238A4 (en) Benzocyclooctyne compounds and uses thereof
IL238959A (en) Glutamase inhibitors, compositions comprising same and uses thereof
SG11201408356VA (en) Novel biocatalyst compositions and processes for use
EP2838954A4 (en) Adhesive compositions and methods
HK1200468A1 (en) Anti-erbb3 antibodies and uses thereof -erbb3
IL243752D0 (en) Multispecific antibodies, compositions comprising same and uses thereof
SG11201404711WA (en) Virus like particle composition
HK1203493A1 (en) Substituted azabicycles and use thereof
ZA201308879B (en) Anti-angptl3 antibodies and uses thereof
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
IL234014A (en) Cycloalkane derivatives, compositions comprising same and uses thereof
SG11201401973TA (en) Anti-fgfr2 antibodies and uses thereof